Ohio State, ETCR license resistant canine hookworm platform
Bottom line
The Ohio State University College of Veterinary Medicine and East Tennessee Clinical Research, or ETCR, said they’ve signed an exclusive commercial license agreement aimed at developing new therapies for multidrug-resistant canine hookworms. Under the deal, Ohio State will continue isolating and characterizing resistant Ancylostoma caninum strains, while ETCR will provide commercial research services, run efficacy studies in animal models, and distribute licensed resistant larvae for approved research use. The announcement follows Ohio State’s isolation and propagation of multidrug-resistant hookworm larvae from a clinical case at its Veterinary Medical Center that did not respond to multiple courses of FDA-approved dewormers. (vet.osu.edu)
Why it matters: For veterinary professionals, this is less about a single licensing deal and more about infrastructure for a growing clinical problem. The American Association of Veterinary Parasitologists formed a Hookworm Task Force in 2021 to address multi-anthelmintic drug-resistant A. caninum, and a 2025 AAVP position paper said genetic evidence suggests multidrug-resistant worms are now widely present in U.S. hookworm populations. Separately, a recent survey found most U.S. veterinarians are aware of multidrug-resistant hookworms, but treatment follow-up and client education, especially around zoonotic risk, still vary. A more standardized source of characterized resistant isolates could help animal health companies generate the efficacy data needed for product development and, potentially, regulatory decision-making. (aavp.org)
What to watch: Watch for ETCR-led efficacy studies, possible partnerships with animal health companies, and whether this platform produces candidate therapies or updated treatment guidance over the next 12 to 24 months. (vet.osu.edu)
Ohio State’s veterinary college and East Tennessee Clinical Research are turning a resistant-parasite discovery into a commercial development platform. In an announcement published April 20, 2026, the organizations said they’ve entered an exclusive license agreement focused on multidrug-resistant canine hookworms, with Ohio State continuing foundational parasite research and ETCR taking on commercial research services, efficacy studies, and distribution rights for licensed resistant larvae. (vet.osu.edu)
The backdrop is a problem that has been building for several years. Reports of canine hookworms resistant to multiple FDA-approved anthelmintic classes first drew broad attention in 2019, and the AAVP created a national Hookworm Task Force in 2021 in response to concern that multidrug-resistant Ancylostoma caninum was moving beyond racing greyhounds into the broader pet dog population. In 2025, the group’s position paper said available genetic evidence suggests multidrug-resistant hookworms are now widely present in the U.S. and called for more work on diagnostics, treatment strategies, and research models. (pmc.ncbi.nlm.nih.gov)
Ohio State said its researchers isolated and propagated multidrug-resistant A. caninum larvae from a clinical case seen at the university’s Veterinary Medical Center after the dog failed multiple courses of FDA-approved deworming therapy. Under the new agreement, Ohio State will keep leading parasite isolation, characterization, and foundational research, while ETCR will use the strains in animal models and provide commercial services to animal health companies evaluating products against resistant hookworm isolates. The deal also allows controlled transfer of characterized resistant larvae for approved research purposes, which could address a practical bottleneck for companies that need validated challenge material to test candidate products. (vet.osu.edu)
The partners are framing the arrangement as a bridge between academic discovery and product development. Ohio State dean Rustin Moore said the collaboration is intended to help advance urgently needed therapeutic solutions, while diagnostic parasitologist Antoinette Marsh said isolating and characterizing resistant parasites creates a scientific foundation for innovation. ETCR president Craig Reinemeyer said the initiative offers a validated platform for evaluating new and existing anthelmintic products against resistant strains and for supporting regulatory-grade study work. ETCR is described as a veterinary parasitology-focused contract research organization that conducts studies intended to support animal health product development and approval. (vet.osu.edu)
Outside reaction from the broader parasitology community underscores why that matters. In a 2025 interview with dvm360, Auburn parasitologist Jeba Jesudoss Chelladurai said veterinarians should assess suspected resistance case by case, confirm resistance diagnostically when possible, and prioritize on-label drugs and combinations before moving to extra-label approaches. That caution reflects a field still working through how best to manage persistent infections while preserving stewardship and staying within regulatory expectations. (dvm360.com)
For veterinary professionals, the significance is practical. Hookworms remain common in U.S. dogs, and a recent survey of 208 veterinarians in 43 states found that while awareness of multidrug-resistant hookworms was generally high, approaches to retesting and client communication were inconsistent. The same study noted that veterinarians often educate pet parents on prevention, but less often on zoonotic risk. A commercialized, characterized resistant-strain platform won’t solve those workflow gaps on its own, but it could speed development of better-supported treatment options and improve the evidence base behind future guidance. (sciencedirect.com)
There’s also a broader One Health angle. A. caninum is primarily a canine parasite, but it has zoonotic relevance through cutaneous larva migrans in humans, and the AAVP position paper explicitly called for collaboration on the implications of multidrug-resistant canine hookworms for human hookworm research. That doesn’t mean this Ohio State-ETCR deal is a human health story today, but it does raise the stakes for surveillance, diagnostics, and environmental control in companion animal practice. (sciencedirect.com)
What to watch: The next signals will be whether ETCR announces sponsored studies with animal health companies, whether Ohio State and collaborators publish additional characterization data on the resistant isolates, and whether the emerging evidence feeds into updated AAVP or practice-level recommendations on diagnosis, retesting, and treatment protocols. (vet.osu.edu)